Skip to content
Clinical Trials – home
FinlandBack to Finland

Clinical trials in Jarvenpaa – page 16

403 clinical trials in Jarvenpaa, Finland. Every trial is listed in the EU Clinical Trials Register and updated daily.

FinlandOur site in FinlandKliinisetTutkimukset.fi(opens in a new tab)
Jarvenpaa at a glance
403
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

403 trials in Jarvenpaa

Open in trial search

Myelodysplastic syndrome

Not yet recruiting

Study of Bexmarilimab with Azacitidine versus Placebo with Azacitidine in Treatment‑Naïve Higher‑Risk Myelodysplastic Syndrome Patients

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bexmarilimab
  • Sponsor:Faron Pharmaceuticals Oy

Subdural haematoma

Not yet recruiting

Effect of Low‑Dose Dexamethasone on Surgical Re‑operation Rate in Adults with Chronic Subdural Hematoma after Burr‑hole Drainage

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:HUS-yhtymae

Breast cancer+2

Not yet recruiting

Gedatolisib with drug combination versus standard therapy as first‑line treatment for patients with advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Celcuity Inc.

C3 glomerulopathy

Not yet recruiting

Pegcetacoplan to Prevent Recurrence of C3 Glomerulopathy or Primary Immune‑Complex MPGN in Adolescent and Adult Kidney Transplant Recipients

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Type 1 diabetes mellitus+1

Not yet recruiting

Dapagliflozin and SC0062 in adults with type 1 diabetes and chronic kidney disease: effect on albuminuria in a Phase 2 randomized trial

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years
  • Substances:Dapagliflozin
  • Sponsor:Universitair Medisch Centrum Groningen

Levofloxacin prophylaxis to reduce bloodstream infections in patients with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years
  • Substances:Levofloxacin
  • Sponsor:HUS-yhtymae

End stage renal disease+1

Not yet recruiting

Safety and efficacy of locally administered APAC, heparin sodium and sodium chloride to promote arteriovenous fistula maturation in patients with end‑stage kidney disease

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Heparin Sodium
  • Sponsor:Aplagon Oy

Gaucher's disease type III

Not yet recruiting

Efficacy and safety of oral venglustat versus intravenous imiglucerase in children aged 2‑11 years with Gaucher disease type 3

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Imiglucerase
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Cardiac sarcoidosis+1

Not yet recruiting

Diagnostic PET Study of Al[18F]F-NOTA-folate in Patients with Suspected Cardiac Sarcoidosis or Infective Endocarditis

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:AL[18F]F-NOTA-FOLATE
  • Sponsor:Turku University Hospital

Embolism venous

Not yet recruiting

Apixaban for Preventing Blood Clots in Adults Receiving Neoadjuvant Therapy for Muscle‑Invasive Bladder Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:HUS-yhtymae

Spinal muscular atrophy

Not yet recruiting

Study of BIIB115 in patients aged 15‑60 years with spinal muscular atrophy who are treatment‑naïve or previously treated with risdiplam

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years
  • Substances:BIIB115
  • Sponsor:Biogen Idec Research Limited

Urinary tract infection

Not yet recruiting

Preventing urinary tract infections in infants and children under 2 years with oral Escherichia coli strain Nissle 1917 probiotic: a randomized controlled trial

Registered drug
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Escherichia coli strain Nissle 1917
  • Sponsor:Pohjois-Pohjanmaan hyvinvointialue

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland

Clinical research in Jarvenpaa

What the registry says about research in the country

01 Respiratory Virus Prevention

Innovative research focusing on respiratory syncytial virus (RSV) and influenza vaccines, evaluating new preventive approaches for both young and elderly populations.

  • RSV vaccine development for seniors
  • Influenza vaccine efficacy studies
  • Combined viral protection research

Multiple clinical trials are exploring breakthrough vaccine technologies, including mRNA platforms.

02 Meningococcal Disease Research

Comprehensive studies on meningococcal vaccines targeting multiple disease strains, with particular focus on protecting infants and young children.

  • Pentavalent vaccine development
  • Long-term immunity studies
  • Pediatric vaccination protocols

Research aims to enhance protection against various meningococcal serogroups through innovative conjugate vaccines.

03 Viral Disease Prevention

Advanced research into preventing cytomegalovirus and herpes zoster infections, utilizing cutting-edge vaccine technologies.

  • CMV prevention strategies
  • Herpes zoster vaccine efficacy
  • Pneumococcal protection studies

These trials focus on developing robust immune responses in specific target populations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.